Group by Gene: Tyrosine Kinase Inhibitors CD Protein Inhibitors Immunotherapy BCL Inhibitors PI3 Kinase Inhibitors Chemotherapy Interleukins Immune Checkpoint Inhibitors MDM2/MDMX Other | zanubrutinib | ibrutinib | BTK inhibitor pirtobrutinib | orelabrutinib | acalabrutinib | M7583 | CD20 inhibitor | CD20 inhibitor obinutuzumab | rituximab | Bcl2 inhibitor, CD20 inhibitor venetoclax + obinutuzumab | venetoclax + rituximab | PI3Kδ inhibitor idelalisib | CD52 inhibitor alemtuzumab | PI3Kδ inhibitor, CD20 inhibitor rituximab + idelalisib | CD52 inhibitor, CD20 inhibitor rituximab + alemtuzumab | PD1 inhibitor pembrolizumab | Bcl2 inhibitor, BTK inhibitor venetoclax + ibrutinib | Bcl2 inhibitor venetoclax | PD1 inhibitor, BTK inhibitor pembrolizumab + ibrutinib | CD19-targeted CAR-T immunotherapy lisocabtagene maraleucel | Alkylating agent chlorambucil | CD19-targeted CAR-T immunotherapy, BTK inhibitor ibrutinib + lisocabtagene maraleucel | obinutuzumab + acalabrutinib | BTK inhibitor, CD20 inhibitor ibrutinib + rituximab | ibrutinib + obinutuzumab | obinutuzumab + zanubrutinib | MDM2 inhibitor, BTK inhibitor acalabrutinib + KRT-232 | PCR | R-CVAD | EPOCH-R | Chemotherapy R-CHOP | BR | FCR | OFAR | T-lymphocyte cell therapy T-lymphocyte cell therapy | BTK inhibitor, Chemotherapy BR + ibrutinib | PI3Kδ inhibitor, Chemotherapy BR + idelalisib | PI3Kγ inhibitor, PI3Kδ inhibitor duvelisib | TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor lenalidomide | TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor rituximab + lenalidomide |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||||||||||||||||||||||||||||||||
TP53 wild-type | ||||||||||||||||||||||||||||||||||||||||
TP53 mutation | ||||||||||||||||||||||||||||||||||||||||
TP53 deletion | ||||||||||||||||||||||||||||||||||||||||
TP53 mutation + Chr del(17p) | ||||||||||||||||||||||||||||||||||||||||
IGH mutation | ||||||||||||||||||||||||||||||||||||||||
BIRC3 mutation | ||||||||||||||||||||||||||||||||||||||||
CD20 positive | ||||||||||||||||||||||||||||||||||||||||
CD19 positive | ||||||||||||||||||||||||||||||||||||||||
ATM mutation | ||||||||||||||||||||||||||||||||||||||||
ALK positive | ||||||||||||||||||||||||||||||||||||||||
BTK C481 | ||||||||||||||||||||||||||||||||||||||||
Chr del(17p) | ||||||||||||||||||||||||||||||||||||||||
Chr del(11)(q22.3) | ||||||||||||||||||||||||||||||||||||||||
Chr del(17)(p13.1) | ||||||||||||||||||||||||||||||||||||||||
Chr del(11q) |